NCT06505291Completed
Long-term Management of Patients With Ruptured HCC
Source: ClinicalTrials.gov · Last updated 17 Jul 2024
Brief summary (registry, in English)
The main objective of this work is to evaluate the prevalence and results of specific management of HCC after spontaneous rupture, since the arrival of sorafenib in 2008.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 112 (actual)
- First submitted
- 25 Jun 2024
- Start date
- 1 Jan 2008
- Primary completion date
- 1 Sept 2023
- Lead sponsor
- University Hospital, Caen
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06505291
What you commit to
- Study type: Observational
- Participants enrolled: 112
- From 1 Jan 2008 to the primary completion date, 1 Sept 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- ATCD of potentially triggering interventional procedure in the previous month.
Other illness
- Other benign or malignant liver tumors
Other
- Liver adenoma without histologically proven HCC
- Hemorrhagic ascites without tumor
- Intratumoral hemorrhages without hemoperitoneum or capsular rupture
Who the study is looking for
- Ruptured hepatocellular carcinoma with or without cirrhosis
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.